Point72 Asia (Singapore) Pte. Ltd. Cassava Sciences Inc Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $646 Billion
- Q3 2025
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Cassava Sciences Inc stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 17,372 shares of SAVA stock, worth $47,946. This represents 0.01% of its overall portfolio holdings.
Number of Shares
17,372
Previous 34,742
50.0%
Holding current value
$47,946
Previous $62.9 Million
19.61%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding SAVA
# of Institutions
136Shares Held
15.9MCall Options Held
1.26MPut Options Held
791K-
Black Rock Inc. New York, NY3.22MShares$8.89 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.29MShares$6.32 Million0.0% of portfolio
-
Marshall Wace, LLP London, X02.06MShares$5.69 Million0.01% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny962KShares$2.65 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY565KShares$1.56 Million0.0% of portfolio
About CASSAVA SCIENCES INC
- Ticker SAVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,097,900
- Market Cap $111M
- Description
- Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...